Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients

Project description

Diagnostic software for reliable personalised cancer treatment

The oncology community widely agrees on the need for personalised cancer treatment decisions. Many patients receive unnecessary treatment, with up to 90 % of those undergoing adjuvant chemotherapy experiencing no benefits and often suffering severe side effects. The EIC-funded Histotype Px project introduces pioneering diagnostic software developed by DoMore Diagnostics (DoMore Dx) that enables personalised cancer treatment in a straightforward and cost-effective manner. This solution uses deep learning algorithms applied to cancer tissue images in local labs equipped with digital pathology tools. In the case of colorectal cancer (CRC), it can categorise patients into low, intermediate, or high-risk groups, potentially sparing up to 250 000 patients from unnecessary chemotherapy.

Objective

There is consensus in the oncology community that there is a large need for personalized cancer treatment decisions as patients suffer from large-scale overtreatment. Up to 90% of patients receiving adjuvant chemotherapy have no effect, many suffer severe side effects. DoMore Diagnostics (DoMore Dx) delivers pioneering diagnostics software that enables personalized cancer treatment in a simple and cost-efficient way. We provide deep learning algorithms applied to cancer tissue whole slide images (WSI) in the adjuvant chemotherapy setting. With end-to-end deep learning we have taken a completely new approach to this challenge. Our test can be run in local labs with digital pathology equipment and does not consume any tissue. DoMore Dx is personalized medicine made simple.
In CRC, our test can stratify patients into low, intermediate, or high risk with a hazard ratio >10. This information can be used to take up to 250,000 patients out of chemotherapy and save 4 billion EUR globally every year.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

DOMORE DIAGNOSTICS AS
Net EU contribution
€ 2 499 999,99
Address
ULLERNSCHAUSSEEN 64
0379 Oslo
Norway
SME
Yes
Region
Norge Oslo og Viken Oslo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 5 326 967,50